34 results about "Glucose Metabolic Disorders" patented technology

The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.

The present invention relates to the use of creatine compounds including cyclocreatine and creatine phosphate for treating or preventing a metabolic disorder consisting of hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of creatine which can act as substrates or substrate analogues for the enzyme creatine kinase; (2) compounds which can act as activators or inhibitors of creatine kinase; (3) compounds which can modulate the creatine transporter (4) N-phosphocreatine analogues bearing transferable or non-transferable moieties which mimic the N-phosphoryl group. (5) compounds which modify the association of creatine kinase with other cellular components.

The present invention provides a blood glucose system having time synchronization, wherein the blood glucose system (1) for treating a glucose metabolic disorder includes a dosing device (3) having an integrated counter for generating a relative count and a memory for storing dose quantities and counts, a blood glucose measuring device (2) having memory for storing blood glucose measurements and measurement times, and a data processor (4) for processing data from the dosing device (3) and blood glucose measuring device (2) and converting counts to actual times. The data processor synchronizes the counts with the measurement times using a time standard.

The invention relates to an application of a black raspberry extract in preparing an anti-diabetic medicine, and an application of the black raspberry extract in preventing type-II diabetes mainly characterized by glucose metabolic disorders, beta islet cell damage and insulin resistance. A novel anti-diabetic medicine preparation provided by the invention takes the black raspberry extract as an active ingredient, and the total effective dose is 1-100mg / kg / d. According to the novel anti-diabetic medicine preparation provided by the invention, the black raspberry extract can be compounded with the diabetes treatment medicines on the current market including sulfonylureas, biguanides or thiazolidinediones to prepare a compound preparation. The black raspberry extract can promote islet cell multiplication and inhibit the PTP1B activity; and meanwhile, in-vivo study finds that the black raspberry extract can be used for improving the increase of the mice blood glucose level caused by alloxan and has an obvious effect in reducing blood glucose. Through verification, the blood glucose reducing effect of the black raspberry fruit or leaf extract is superior to that of the selected positive medicine diaformin.

Leptin resistance ameliorating agents comprising as the active ingredient a neurotrophic factor such as BDNF or a trk receptor ligand, namely, agents for ameliorating, treating or preventing hypertension, sterility, obesity, glucose metabolic disorders, ischemic diseases, growth hormone secretion insufficiency, growth hormone hyposecretion, immune function disorder, etc. caused by leptin resistance.

The invention discloses a method for providing a new intervention target for preparation of antihyperglycemic medicines and using the irisin into development of diabetes-related medicines to prepare relatively good medicines for treating diabetes. After STZ / HFD-induced mice with diabetes are subjected to subcutaneous injection with irisin, the fasting serum glucose level is significantly reduced; the insulin sensitivity is significantly improved; by irisin, gluconeogenesis is reduced and glycogen synthesis is increased; the application proves that irisin is capable of significantly improving glucose metabolic disorder and insulin resistance in diabetes, is an effective target for treating diabetes, and can be developed as a novel antihyperglycemic medicine or medicine target; and a new way and means are provided for detection and treatment of diabetes.

The invention provides an alpha-mangostin derivative and application thereof in preparation of a metabolic syndrome preventing and / or treating medicine. Through experimental proof, the alpha-mangostin derivative can simultaneously improve multiple metabolic disorders factors, and can obviously improve abnormal lipids metabolism, increase insulin sensitivity and reduce blood pressure. The compound provided by the invention has obvious treatment effect for the metabolic syndromes caused by gathering of the factors such as the abnormal lipids metabolism, blood pressure abnormity, blood glucose metabolic disorder and obesity and can be used as a metabolic syndrome clinic treatment medicine for use.

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance / glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and / or polycystic ovary disease.

Assays methods for clinical evaluation of conditions that might be treated with copper antagonists. These conditions include diabetes and other glucose metabolism disorders, lipid disorders, neurological disorders, and heart disease. The assays utilize a correlation between copper levels and one or more of the markers hemoglobin AIc and extracellular superoxide dismutase activity, in order to detect the condition, predict progression of the condition and assess a patient's response to copper antagonist therapy in these conditions by monitoring the level of these markers.

In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

The invention provides a blood-sugar-reducing nutritious glue pudding and a making method thereof. The glue pudding comprises a wrapper and stuffing. The wrapper comprises, by mass percent, 60-85% of glutinous rice flour, 0.3-0.9% of radix pseudostellariae powder, 1.2-3% of emblic fruit powder, 2.5-8% of chickpea spout powder, 5-15% of buckbean and 3-10% of costus root. The glue pudding is made by wrapping the stuffing with the wrapper. The glue pudding has the advantages that fragrance, sweetness, deliciousness, smoothness and glutinousness of traditional glue pudding are kept, nutrition balancing and dietary therapy health care are achieved, and functions of blood sugar regulating and lowering and diabetes treatment aiding are added. Frequent eating of the glue pudding can nourish liver and kidney, tonify qi and produce blood, boost immunity, increase sugar tolerance (OCTT) and glycosylated hemoglobin (HbALC) level, regulate human body internal secretion, correct glucose metabolic disorder, restore islet function, allow blood sugar to be normal, and prevent complication. The blood-sugar-reducing nutritious glue pudding is ideal health-care nutritious food for diabetes patients and people with high blood sugar, and nutrition and health-care effects can be achieved for normal people eating the glue pudding.

The invention discloses a compound silkworm pupa hypoglycemic health-care medicinal composition as well as a preparation method and application thereof, belonging to the fields of biotechnology and traditional Chinese medicine and pharmacy. The compound silkworm pupa hypoglycemic health-care medicinal composition is innovated specific to the aims of stabilizing and correcting glucose metabolic disorder from the aspect of human body metabolism on the basis of keeping and strengthening original functional factors of silkworm or silkworm chrysalis meal including insect insulin (IGF-1) and 1-deoxynojirimycin (DNJ) and the like by adding essential nutrient factors which are beneficial to anti-oxidation of human bodies, immunoregulation, regulation of blood sugar and the like in a scientific combination way. As proved by experiments, the compound silkworm pupa hypoglycemic health-care medicinal composition disclosed by the invention lowers fasting blood-glucose, enhances the sugar tolerance and remarkably improves the clinical symptoms of a diabetic patient.

The invention relates to a novel PPAR gamma / delta dual agonist as shown in a general formula (I) which is described in the specification, a preparation method thereof and an application of a pharmaceutical composition containing the derivative in preparation of drugs for preventing or / and treating glucose metabolic disorder or / and lipid metabolic disorder diseases. The PPAR gamma / delta dual agonist has excellent in-vivo hypoglycemic activity and blood fat regulating effect, can be applied to preparation of drugs for preventing or / and treating metabolic syndrome related diseases such as diabetes, obesity, hyperlipidemia, atherosclerosis, fibrosis and fatty liver, and has a wide application prospect.

The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis / trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.

The invention discloses a method for preparing a Kinase protein Akt1 conditional gene knockout non-human mammal model and application of the method. The invention further discloses a method for screening compounds for preventing or treating cardiomegaly and glucose metabolic disorders by the Kinase protein Akt1 conditional gene knockout non-human mammal model, and application of the model that Akt1 and upstream and downstream biological signal transduction pathways of the Akt1 serve as medicine intervention targets to treat cardiomegaly and glucose metabolic disorders.

The invention discloses a compound silkworm pupa hypoglycemic health-care medicinal composition as well as a preparation method and application thereof, belonging to the fields of biotechnology and traditional Chinese medicine and pharmacy. The compound silkworm pupa hypoglycemic health-care medicinal composition is innovated specific to the aims of stabilizing and correcting glucose metabolic disorder from the aspect of human body metabolism on the basis of keeping and strengthening original functional factors of silkworm or silkworm chrysalis meal including insect insulin (IGF-1) and 1-deoxynojirimycin (DNJ) and the like by adding essential nutrient factors which are beneficial to anti-oxidation of human bodies, immunoregulation, regulation of blood sugar and the like in a scientific combination way. As proved by experiments, the compound silkworm pupa hypoglycemic health-care medicinal composition disclosed by the invention lowers fasting blood-glucose, enhances the sugar tolerance and remarkably improves the clinical symptoms of a diabetic patient.

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.

The invention relates to application of a polyketone compound in treatment of metabolic disorder related diseases, in particular to application of a compound shown as a formula I, a tautomer of the compound and pharmaceutically acceptable salt or ester of the compound in preparation of drugs, and the drugs are used for preventing or treating lipid and / or glucose metabolic disorder related diseases.

Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The ThrB30-GluA4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. The ester insulin is readily prepared by total chemical synthesis, and amendable to cost-effective, large scale manufacturing. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods. Also provided are methods of using the subject compositions and kits in the treatment of a variety of different disease conditions, particularly glucose metabolic disorders such as diabetes and obesity.

The invention discloses a secretion-type FNDC5 protein. The secretion-type FNDC5 protein does not contain a transmembrane domain and can be directly secreted and released into blood; and the amino acid sequence of the FNDC5 protein is SEQ ID NO:1. The secretion-type FNDC5 protein is simple in structure and convenient to obtain. The secretion-type FNDC5 protein can be used for treating obesity-related metabolic disorders; after the secretion-type FNDC5 recombinant protein is injected into the abdominal cavity of a high-fat fed obese mouse model, glucose and insulin tolerance can be effectivelyimproved, and it shows that the protein can obviously relieve glucose metabolic disorders and insulin resistance of obese patients; and fatty liver occurrence can be obviously relieved, the level of plasma cholesterol, free fatty acid and triglyceride is decreased, and it shows that the protein can relieve the lipometabolic disorders of the obese patients. The secretion-type FNDC5 protein can serve as a new drug target for treating the metabolic disease to be developed.

The invention discloses panax ginseng stem leaf effective parts, an extracting method thereof and application of the panax ginseng stem leaf effective parts in lowering the blood glucose, and belongsto the field of drugs. The panax ginseng stem leaf effective parts comprise, by mass, 1-30% of ginsenoside Rg1, 10-40% of ginsenoside Re, 1-20% of ginsenoside Rb2 and 1-30% of ginsenoside Rd. The invention further discloses the extracting method of the panax ginseng stem leaf effective parts and the application of the panax ginseng stem leaf effective parts in treating diabetes. The panax ginsengstem leaf effective parts can correct glucose metabolic disorders, lower fasting blood glucose, reduce impaired glucose tolerance, improve insulin resistance and insulin sensitivity, and have the function of treating or preventing diabetes and complications of the diabetes.

The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis / trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.

The invention discloses application of Baatimatat to preparation of a medicine for preventing and treating obesity and secondary bone loss. According to the invention, a mouse high-fat diet obesity model is utilized to simulate the most common primary obesity in people; the in-vivo biological efficacy of the Batimatat is evaluated through multiple dimensions such as weight, glycometabolism, adipose tissue change, bone metabolism and the like; the fact that the Batimatat can be applied to prevention and treatment of obesity caused by over-differentiation and accumulation of adipocytes and concomitant complications of glucose metabolic disorders, osteopenia and the like is defined for the first time; and the Batimatat takes a relatively remarkable effect.

The invention relates to a human body nutrient diagnosis instrument which adopts multiple pieces of equipment to comprehensively collect the height, the weight, the hip circumference, the waist circumference, the chest circumference, the BMI (Body Mass Index), the basic metabolism, the bone density, the body fat rate, the abdominal fat and the trace elements of the human body, and a fundus retinablood vessel change characteristic and pulse wave parameter system carries out synthetic analysis for nutrient diagnosis; according to fundus retina blood vessel change characteristics and a lesion mechanism, cell function injuries brought by glucose metabolic disorders are comprehensively judged; and blood pressure blood vessel change is used for judging the elasticity of a blood vessel wall andthe fat type of the blood vessel wall so as to accurately analyze the content of 50 kinds of nutrients of the human body and a potential quantity demanded so as to give a corresponding dietary nutrition treatment solution. The human body nutrient diagnosis instrument is safe and convenient since a blood test is not required, and is favorable for the nutrient diagnosis requirements of common people.

The invention discloses a compound with glucose-reducing and lipid-regulating effects as well as a preparation and application thereof. The compound with glucose-reducing and lipid-regulating effectsis a compound with structures as shown in a formula I and a formula II and a pharmaceutically acceptable salt, wherein the structures as shown in the formula I and the formula II are specifically shown in the specification. The preparation is a tablet, a capsule, powder, a pill or an injection prepared by adding pharmaceutically acceptable auxiliary materials into the compound with the glucose-reducing and lipid-regulating effects. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparing an FFA1 / PPARdelta dual agonist. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparation of drugs for preventing and / or treating glucose metabolic disorder and / or lipid metabolic disorder diseases. The compound and the medicinal salt thereof can be potentially used for treating or preventing diabetes, hyperlipidemia, fatty liver and other related metabolic syndromes, and have wide development prospects.